--- title: "Your Term Sheet Has a Clause That Hands Your IP to Your Investor. You Already Signed It." slug: ip-term-sheet-trap-founders date: 2026-04-08 url: https://beyondelevation.com/blog/post.html?slug=ip-term-sheet-trap-founders author: Hayat Amin site: Beyond Elevation --- # Your Term Sheet Has a Clause That Hands Your IP to Your Investor. You Already Signed It. A $12M Series A. Two licensable patents. An $800K-per-year royalty deal on the table. Killed in a single email from the founder's own investor. The reason was on page 14 of the term sheet. A blanket security interest over all company intellectual property. Every patent. Every trade secret. Every line of proprietary code. The investor had veto power over any IP transaction — and the founder did not know the clause existed until Beyond Elevation reviewed the agreement six months after closing. His startup lawyer had not flagged it. The investor's counsel had drafted it as boilerplate. And this is not a one-off horror story. It is the default. Roughly 70% of the venture-backed term sheets that Beyond Elevation reviews contain IP provisions that restrict the founder's ability to license, sell, or leverage their own patents. Your IP is probably the most valuable asset your company owns. And there is a very good chance you have already signed away control of it. ## What Are the IP Clauses in Term Sheets That Cost Founders Millions? Four IP provisions appear in standard term sheets and venture loan agreements. None of them are illegal. All of them are negotiable. Most founders never push back because they do not know these clauses exist until the damage is done. ### 1. The Blanket IP Security Interest This is the most common and the most dangerous. It grants the investor or lender a security interest in all company intellectual property as collateral. If the company defaults — or in some agreements, merely trips a financial covenant — the investor can seize your patents, trademarks, copyrights, and trade secrets. In practical terms, it also means any licensing deal, IP sale, or patent cross-licence with a partner may require investor consent. That $800K-per-year royalty deal from the opening? Dead on arrival because the investor's counsel would not approve it. The IP was collateral. You do not get to rent out collateral without the bank's permission. ### 2. The Acceleration Assignment Clause Some term sheets include language that assigns company IP to the investor's designated entity upon an acceleration event. These triggers can include missing a revenue milestone, failing to raise a follow-on round, or breaching a financial covenant. In one case Beyond Elevation reviewed, the acceleration trigger was the company falling below a 1.2x debt service coverage ratio for two consecutive quarters. The founder had not missed a single payment. But his ratio dipped to 1.15 during a seasonal slowdown — and technically, the investor could have exercised the clause to take ownership of 11 granted patents. That is not a default. That is a rounding error. And the patents were on the line. ### 3. The Overbroad "Company IP" Definition Standard term sheets define "Company Intellectual Property" as all IP created by the company, its employees, or its contractors during the term of the agreement. That sounds reasonable. But many definitions also sweep in pre-existing IP that the founder contributed — patents filed before incorporation, algorithms developed before the company existed, and proprietary datasets brought in as founder contributions. If you brought IP into the company and the term sheet does not explicitly carve it out, it is now collateral. One founder Beyond Elevation worked with had three provisional patents filed 18 months before incorporation. All three were swept into a blanket security interest because the definition of Company IP included "all intellectual property used in the business." Eight words. Three patents gone. ### 4. The Anti-Monetisation Restriction This clause requires investor consent before the company can license, sell, transfer, or encumber any IP asset. On the surface, it protects the investor's collateral. In practice, it blocks the single most effective non-dilutive revenue strategy available to patent-rich startups: licensing. Companies with structured IP licensing programmes generate a median of $2.1M in annual recurring revenue from their patent portfolios, according to Ocean Tomo analysis. But if your term sheet requires investor sign-off on every licensing deal, most potential licensees walk. The legal friction alone kills the economics. You are not just losing one deal. You are losing an entire revenue channel. ## How Do Smart Founders Negotiate IP Clauses in Term Sheets? The fix is not to reject these clauses outright. That signals inexperience and can kill a deal. The fix is to negotiate specific carve-outs that protect your ability to monetise and control your IP while still giving investors reasonable security. Here is what Beyond Elevation recommends founders demand before signing: **Carve out licensing revenue.** Negotiate an explicit exception that allows the company to enter into non-exclusive patent licences without investor consent, provided the licence does not transfer ownership. This preserves your ability to generate recurring royalty income — the revenue stream that makes your next round easier, not harder. **Ring-fence pre-existing IP.** Attach a schedule to the term sheet that lists all IP created prior to incorporation or investment. Exclude it from the security interest. If you do not list it, you lose it. This takes an afternoon. Skipping it can cost you millions. **Cap the security interest.** Instead of a blanket lien on all IP, negotiate a security interest limited to specific patents or patent families directly relevant to the funded product. This keeps your broader portfolio free for licensing and cross-licensing. **Add a cure period.** For acceleration clauses, negotiate a 90-day cure period before any IP assignment can be triggered. This gives you time to fix a covenant breach before losing your most valuable assets to a technicality. **Get an IP valuation on the table early.** When investors see that your patent portfolio has been independently valued at $8M, they treat it differently than when it is an undifferentiated line item on a cap table. Position Imaging's 66-patent portfolio, restructured by Beyond Elevation, did exactly this — and the valuation changed every subsequent negotiation. Numbers on paper become leverage at the table. ## Why Does This Matter Right Now? Companies with patents are 10.2x more likely to secure early-stage funding. But securing funding with IP and retaining control of that IP are two entirely different outcomes. The irony is brutal: the very asset that got you funded is the one most likely to be locked up by the terms of the deal that funded you. Beyond Elevation has reviewed over 200 term sheets for tech and AI founders. In roughly 70% of cases, the IP provisions needed significant renegotiation. In nearly every case, the founder had not read them before signing. The founders who avoid this trap are the ones who get an IP strategy review before they sign — not six months after. ## Frequently Asked Questions ### Can an investor actually take my patents if I default? Yes. If your term sheet includes a blanket IP security interest with an assignment-on-default provision, the investor or lender can legally seize and take ownership of your patents, trademarks, copyrights, and trade secrets upon a qualifying default. The definition of "default" varies by agreement but can include missed milestones, covenant breaches, and failure to raise subsequent funding. Beyond Elevation has reviewed cases where this has been exercised — it is not theoretical. ### Should I refuse to give an IP security interest to my investor? No. Refusing outright signals inexperience and will likely kill your deal. The correct strategy is to negotiate targeted carve-outs: exclude pre-existing IP, cap the security interest to specific patent families, permit non-exclusive licensing without consent, and add cure periods before acceleration triggers. Beyond Elevation helps founders structure these carve-outs before term sheets are signed so the negotiation is clean and professional. ### How do I know if my current term sheet has these clauses? Search your term sheet and any related loan, SAFE, or convertible note documents for these exact phrases: "security interest," "Company Intellectual Property," "collateral," "assignment upon acceleration," and "consent to licence." If any of these appear without explicit carve-outs protecting your licensing rights and pre-existing IP, your portfolio is likely encumbered. Beyond Elevation offers a term sheet IP audit that identifies these provisions and provides specific redline recommendations. ### When should I get an IP valuation before a fundraise? Before the term sheet is drafted — not after. An independent IP valuation gives you a concrete number to anchor negotiations. It shifts the conversation from "we have some patents" to "our IP portfolio is independently valued at $X and structured for licensing revenue." Beyond Elevation uses income-based, market-comparable, and cost-based methodologies to produce defensible valuations, typically in two to four weeks. Position Imaging's 66-patent portfolio restructuring is proof that this changes the entire dynamic. If you are raising capital and your IP strategy stops at "we filed patents," you are leaving leverage and money on the table. The term sheet is where fortunes are made or given away — and the IP clause is the one most founders never read. Beyond Elevation builds the IP architecture that keeps founders in control before they sign. Start at [beyondelevation.com](https://beyondelevation.com). --- *Published on [Beyond Elevation](https://beyondelevation.com) — IP Strategy & Licensing Revenue Consultancy*